Emerging biotechnologies: full report - Nuffield Council on Bioethics
Emerging biotechnologies: full report - Nuffield Council on Bioethics
Emerging biotechnologies: full report - Nuffield Council on Bioethics
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
E m e r g i n g b i o t e c h n o l o g i e s<br />
Index<br />
Locators point to paragraph or box numbers. Footnotes are indexed to the paragraph (or box) number<br />
that they relate to; some topics appear <strong>on</strong>ly in the footnotes.<br />
academic entrepreneurialism 6.39<br />
Academy of Medical Sciences 7.46<br />
accountability<br />
regulatory systems 8.24–8.25, 8.29<br />
virtue of 4.47–4.48<br />
Acti<strong>on</strong> <strong>on</strong> Hearing Loss 6.14<br />
adalimumab 9.3<br />
advisors, policy 4.36<br />
see also scientific advisors<br />
Advisory Committee <strong>on</strong> Releases to the<br />
Envir<strong>on</strong>ment 8.24<br />
Advisory Committee <strong>on</strong> the Misuse of Drugs<br />
8.24<br />
advisory framework, UK 7.6–7.9<br />
advisory panels/groups 7.52–7.54<br />
see also scientific advisory committees<br />
age-related macular degenerati<strong>on</strong> 3.9<br />
Agreement <strong>on</strong> Trade Related Aspects of<br />
Intellectual Property Rights (TRIPS)<br />
9.19, 9.39<br />
agricultural biotechnology 1.8, 2.8–2.9, 5.16,<br />
9.4<br />
Agriculture and Envir<strong>on</strong>ment Biotechnology<br />
Commissi<strong>on</strong> (AEBC) 7.7<br />
agrochemicals 9.17, 9.19<br />
ambiguity 3.1, 3.13–3.21, 3.37–3.38, 10.4<br />
effects of framing 3.35–3.36<br />
managing 3.26–3.36<br />
objects 3.19–3.20<br />
practices 3.17–3.18<br />
public discourse ethics 4.44<br />
public perspectives 5.3<br />
regulatory aspects 8.12–8.14, 8.35<br />
serious implicati<strong>on</strong>s 3.21<br />
visi<strong>on</strong>s 3.14–3.16<br />
anarcho-capitalism Box 9.2<br />
angel investors 6.13<br />
antibiotics 1.10, 2.21<br />
anticipatory paradigm 3.25, 6.29<br />
anti-malarial drugs 2.21, Box 9.3<br />
antisense RNA 2.13<br />
Arch2POCM Box 9.3<br />
Aristotle 4.12, 4.18<br />
arteminisinic acid 2.21, 2.23<br />
Arthritis Research UK 7.18<br />
asbestos 3.8, Box 1.1<br />
Asilomar c<strong>on</strong>ference (1975) 8.20<br />
ATryn (anticoagulant drug) 2.10<br />
attitudes to biotechnology 1.4–1.6, Box 1.1<br />
aut<strong>on</strong>omy, of living beings 4.11–4.12<br />
availability heuristic Box 3.4<br />
Avastin® 3.9<br />
avian influenza virus 8.11, Box 3.1<br />
Bacillus thuringiensis (Bt) cott<strong>on</strong> Box 9.2<br />
bacteria, synthetic 2.20, Box 3.2<br />
balance sheet, biotechnology 1.7–1.12<br />
Beddingt<strong>on</strong>, Sir John 6.36<br />
benefits (of <str<strong>on</strong>g>biotechnologies</str<strong>on</strong>g>)<br />
ambiguities 3.14–3.16<br />
assessing past policies 7.46, 10.14<br />
attitudes 1.5, Box 1.1<br />
biotechnology wager 1.1–1.2<br />
ec<strong>on</strong>omic see ec<strong>on</strong>omic growth<br />
ethical c<strong>on</strong>siderati<strong>on</strong>s 4.23–4.27, 4.50–<br />
4.51, 4.56<br />
examples 1.7–1.12<br />
expectati<strong>on</strong>s see expectati<strong>on</strong>s<br />
public nature 4.4<br />
sceptical approach 2.39–2.44<br />
uncertainties 3.5–3.7<br />
beta-lymphocyte stimulators 9.64<br />
bevacizumab 3.9<br />
Big Pharmaceutical Firms (BPFs) 9.9–9.10<br />
Bill and Melinda Gates Foundati<strong>on</strong> 6.14, 6.37<br />
bioart 6.54<br />
BioBricks® 1.14, 2.19, 8.25, 9.46<br />
bioethics, re-orientati<strong>on</strong> of 4.20–4.21<br />
biofuels 1.9, 2.21, 2.28, 2.33, 9.70<br />
biohackers 2.37<br />
bioinformatics 2.17<br />
biological, defined 2.3<br />
biological drugs 2.12<br />
biological revoluti<strong>on</strong> 7.42<br />
biological weap<strong>on</strong>s 3.9, Box 3.1, 8.10<br />
biomanufacturing 9.37, 9.40<br />
biomedicine 1.10<br />
bio-optimism 1.4–1.6, 2.41, 2.44<br />
bio-pessimism 1.4–1.6, 2.44<br />
biopharmaceuticals (biopharma) 2.12, 9.3<br />
intellectual property rights 9.35–9.36<br />
see also drugs<br />
bioreactors 9.37, 9.40, 9.70<br />
bioremediati<strong>on</strong> 3.5, 4.7–4.8<br />
biosafety 8.4–8.8<br />
biosecurity 8.4–8.8<br />
dual-use problem 8.9–8.11<br />
Biosteel® 2.10, 2.28<br />
biotechnology<br />
definiti<strong>on</strong>s 1.13, 2.2–2.4<br />
emergence see emergence of<br />
<str<strong>on</strong>g>biotechnologies</str<strong>on</strong>g><br />
main fields 2.5–2.27<br />
types of activities 9.34–9.37<br />
visi<strong>on</strong>s 2.29–2.38<br />
Biotechnology and Biological Sciences<br />
Research <str<strong>on</strong>g>Council</str<strong>on</strong>g> (BBSRC) 6.7, 7.4,<br />
7.16<br />
198